The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

103 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-20

Study Completion Date

2019-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if Xiidra® lifitegrast plays a role in the refractive accuracy when administered to patients preoperatively who are scheduled for cataract surgery and have a tear break up time (TBUT) ≤ 10 seconds and central corneal staining as defined by the Oxford scale

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396

Dry Eye

COMPLETED PHASE4

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

NCT04669561

Dry Eye

COMPLETED PHASE4

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

NCT01743729

Dry Eye Disease

COMPLETED PHASE3

Effect of Lifitegrast 5% on Tear Film Markers

NCT03952481

Dry Eye Dry Eye Syndromes Dry Eyes Chronic

WITHDRAWN PHASE4

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

NCT04172961

Dry Eye

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a 4-week multicenter investigator-initiated study, in which a maximum of 200 subjects will be enrolled.

As many as two thirds of patients undergoing cataract surgery have dry eye. Often this latter condition is under treated i.e., any dry eye treatment such as artificial tears, that is being pursued in not adequately controlling the visually significant ocular surface disruption, and patient still have corneal staining or a reduced tear break-up time (TBUT).

The investigators hypothesize that lifitegrast administered at least 4-week prior to pre-operative biometry measurements will improve both the quality of measurements used to choose an intraocular lens implant for surgery and the symptoms of patients with this combination of conditions. This finding would suggest that pre-treatment with lifitegrast can improve both the accuracy of surgery and patient comfort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lifitegrast 5%

Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.

Lifitegrast

Intervention Type DRUG

Lifitegrast ophthalmic solution 5%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lifitegrast

Lifitegrast ophthalmic solution 5%

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with planned cataract surgery
2. Central or inferior corneal fluorescein staining defined by the Oxford Scale
3. Reduced tear break up time (TBUT) ≤ 10 seconds.
4. Able to comprehend and sign a statement of informed consent.
5. Willing and able to complete all required postoperative visits.

Exclusion Criteria

1. Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure
2. Clinically significant ocular trauma.
3. Active ocular Herpes simplex or Herpes Zoster infection
4. Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
5. Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
6. Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the questions in the survey and examination findings.
7. Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.
8. Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
9. Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
10. Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
11. Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to enrollment date.
12. Participation in this trial in the same patient's fellow eye
13. Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes